Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:43:41 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:LEGN from 2023-05-04 to 2024-05-03 - 46 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 13:05U:LEGNNews ReleaseCARVYKTI(TM) (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
2024-04-11 08:00U:LEGNNews ReleaseLegend Biotech to Host Investor Conference Call on First Quarter 2024 Results
2024-04-05 23:30U:LEGNNews ReleaseLegend Biotech's CARVYKTI(TM) (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
2024-03-19 08:30U:LEGNNews ReleaseLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
2024-03-15 15:15U:LEGNNews ReleaseCARVYKTI(TM) (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
2024-03-11 07:00U:LEGNNews ReleaseLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
2024-02-23 07:15U:LEGNNews ReleaseLegend Biotech Announces Positive CHMP Opinion for CARVYKTI(TM) (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
2024-02-13 08:00U:LEGNNews ReleaseLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
2024-01-03 08:30U:LEGNNews ReleaseLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
2024-01-02 08:30U:LEGNNews ReleaseLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 19:30U:LEGNNews ReleasePatient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI ‚ ® (ciltacabtagene autoleucel)
2023-12-11 07:33U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-10 07:32U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-08 10:17U:LEGNNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN
2023-12-08 07:32U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-07 07:46U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-07 07:32U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-06 14:46U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-06 07:47U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-06 07:32U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-05 07:59U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-05 07:31U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-04 16:31U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-04 07:46U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-04 07:32U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-03 08:03U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-12-03 07:31U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-02 13:05U:LEGNNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN
2023-12-01 09:21U:LEGNNews ReleaseLegend Biotech Corporation (LEGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
2023-12-01 07:46U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-11-30 16:01U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-11-30 12:22U:LEGNNews ReleaseSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Legend Biotech Corporation (LEGN)
2023-11-20 06:00U:LEGNNews ReleaseLegend Biotech Reports Third Quarter 2023 Results and Recent Highlights
2023-11-13 08:30U:LEGNNews ReleaseLegend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
2023-11-07 08:30U:LEGNNews ReleaseLegend Biotech to Host Investor Conference Call on Third-Quarter Results
2023-11-02 09:17U:LEGNNews ReleaseLegend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
2023-08-15 06:00U:LEGNNews ReleaseLegend Biotech Reports Second Quarter 2023 Results and Recent Highlights
2023-08-03 08:30U:LEGNNews ReleaseLegend Biotech to Host Investor Conference Call on Second-Quarter Results
2023-06-06 16:30U:LEGNNews ReleaseLegend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI ‚ ® (ciltacabtagene autoleucel)
2023-06-05 11:04U:LEGNNews ReleaseCiltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
2023-06-02 16:01U:LEGNNews ReleaseLegend Biotech Announces Participation in Upcoming Investor Conferences
2023-05-25 08:30U:LEGNNews ReleaseLegend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI ‚ ® (ciltacabtagene autoleucel)
2023-05-18 08:30U:LEGNNews ReleaseLegend Biotech Reports First Quarter 2023 Results and Recent Highlights
2023-05-16 08:35U:LEGNNews ReleaseLegend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
2023-05-11 16:01U:LEGNNews ReleaseLegend Biotech Announces Participation in Upcoming Investor Conference
2023-05-08 08:30U:LEGNNews ReleaseLegend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares